TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

NEXT STORY
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
PREV STORY
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117

ROCKVILLE, Md., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a ...

author_avatar
NASDAQ Market News

Resverlogix to Participate in Leading Scientific Conferences

author_avatar
NASDAQ Market News

Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting

HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new ...

author_avatar
NASDAQ Market News